Healthcare stocks are little changed, with the NYSE Healthcare
Sector Index and shares of healthcare companies in the S&P 500
both slipping less than 0.1% as a group.
In company news, Ariad Pharmaceuticals (
) still is down more than 69% at $5.29 a share but is well off its
new 52-week low that carried shares to $4.00 each after the Food
and Drug Administration placed a partial hold on new patient
enrollments in clinical trials for its Iclusig drug candidate after
some patients suffered from serious side effects including blood
clots and other cardiac problems.
ARIA said just under 12% of patients receiving the prospective
cancer pill developed blood clots during the past two years. That's
a 50% increase over its prior reports on the drug's side effects.
Overall, about one out of five patients experienced some side
effect from Iclusig during testing so far, according to the
ARIA reported $13.9 million in Iclusig sales during Q2. Pending
FDA approval, the company said it plans to continue enrollment in
clinical studies of the drug using lower doses.
In other sector news,
(+) ATEC, (+5.7%) Sees Q3 revenue rising 7% year over year to
$50.1 mln, topping Street estimates by $1.64 mln, with solid unit
volume gains in core hospital business and higher surgeon uptake
across various product line in the U.S.
(-) LPTN, (-16.0%) Pfizer Inc (
) tells the biotech it will divest some of its ophthalmology
R&D assets, including an option to commercialize LPTN's iSONEP
treatment for wet age-related macular degeneration. LPTN has
offered to reacquire those rights.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.